JP2010533189A - 口腔疾患を予防するための組成物および方法 - Google Patents
口腔疾患を予防するための組成物および方法 Download PDFInfo
- Publication number
- JP2010533189A JP2010533189A JP2010516078A JP2010516078A JP2010533189A JP 2010533189 A JP2010533189 A JP 2010533189A JP 2010516078 A JP2010516078 A JP 2010516078A JP 2010516078 A JP2010516078 A JP 2010516078A JP 2010533189 A JP2010533189 A JP 2010533189A
- Authority
- JP
- Japan
- Prior art keywords
- gram
- chlorine dioxide
- bacteria
- oral
- streptococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 32
- 239000000203 mixture Substances 0.000 title abstract description 20
- 208000025157 Oral disease Diseases 0.000 title abstract description 15
- 208000030194 mouth disease Diseases 0.000 title abstract description 15
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims abstract description 172
- 241000894006 Bacteria Species 0.000 claims abstract description 97
- 239000004155 Chlorine dioxide Substances 0.000 claims abstract description 86
- 235000019398 chlorine dioxide Nutrition 0.000 claims abstract description 86
- 230000002147 killing effect Effects 0.000 claims abstract description 20
- 230000000813 microbial effect Effects 0.000 claims abstract description 20
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 18
- 230000001580 bacterial effect Effects 0.000 claims description 67
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 35
- 208000028169 periodontal disease Diseases 0.000 claims description 29
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 25
- 230000003239 periodontal effect Effects 0.000 claims description 25
- 210000000214 mouth Anatomy 0.000 claims description 24
- 244000052769 pathogen Species 0.000 claims description 24
- 241000186046 Actinomyces Species 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 241000194023 Streptococcus sanguinis Species 0.000 claims description 21
- 241000589996 Campylobacter rectus Species 0.000 claims description 15
- 241000194032 Enterococcus faecalis Species 0.000 claims description 14
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 14
- 241000194025 Streptococcus oralis Species 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 230000014616 translation Effects 0.000 claims description 12
- 241001464887 Parvimonas micra Species 0.000 claims description 11
- 235000013355 food flavoring agent Nutrition 0.000 claims description 10
- 241001135221 Prevotella intermedia Species 0.000 claims description 8
- 241000194017 Streptococcus Species 0.000 claims description 8
- 241000192125 Firmicutes Species 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 241000589876 Campylobacter Species 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 241000122116 Parvimonas Species 0.000 claims description 5
- 241000191992 Peptostreptococcus Species 0.000 claims description 5
- 241001148471 unidentified anaerobic bacterium Species 0.000 claims description 5
- 241000194033 Enterococcus Species 0.000 claims description 4
- 230000035699 permeability Effects 0.000 claims description 4
- 241001148470 aerobic bacillus Species 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims 4
- 241000555745 Sciuridae Species 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 abstract description 49
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 30
- 239000002324 mouth wash Substances 0.000 abstract description 17
- 206010006326 Breath odour Diseases 0.000 abstract description 12
- 239000000243 solution Substances 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 6
- 208000032139 Halitosis Diseases 0.000 abstract description 3
- 239000000725 suspension Substances 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 29
- 201000001245 periodontitis Diseases 0.000 description 24
- 238000012360 testing method Methods 0.000 description 19
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 230000034994 death Effects 0.000 description 9
- 238000001243 protein synthesis Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 208000007565 gingivitis Diseases 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000030833 cell death Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000005107 Premature Birth Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- -1 staherins Proteins 0.000 description 6
- 150000003464 sulfur compounds Chemical class 0.000 description 6
- 241000186044 Actinomyces viscosus Species 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 208000018773 low birth weight Diseases 0.000 description 5
- 231100000533 low birth weight Toxicity 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000002064 Dental Plaque Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000003899 bactericide agent Substances 0.000 description 4
- 239000000022 bacteriostatic agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006161 blood agar Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 3
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 241000589892 Treponema denticola Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 241000606750 Actinobacillus Species 0.000 description 2
- 241001024600 Aggregatibacter Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241001470488 Tannerella Species 0.000 description 2
- 241001135235 Tannerella forsythia Species 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 229910001919 chlorite Inorganic materials 0.000 description 2
- 229910052619 chlorite group Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000033040 negative regulation of metabolic process Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 241000186066 Actinomyces odontolyticus Species 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589873 Campylobacter concisus Species 0.000 description 1
- 241000190890 Capnocytophaga Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000108056 Monas Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007457 Oral Manifestations Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 101100113068 Petunia hybrida CFAT gene Proteins 0.000 description 1
- 241001135213 Porphyromonas endodontalis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 101710136733 Proline-rich protein Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 1
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 1
- 241000224974 Streptococcus oralis ATCC 35037 Species 0.000 description 1
- 241000775081 Streptococcus sanguinis SK1 = NCTC 7863 Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 241001148135 Veillonella parvula Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000025845 adhesion to host Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011482 antibacterial activity assay Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000002986 dental sac Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000009034 developmental inhibition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002289 effect on microbe Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000009836 endodontic lesion Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 210000001648 gingival epithelial cell Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000007406 plaque accumulation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000012423 response to bacterium Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036185 rubor Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【選択図】 図1
Description
歯垢は、最近では“歯の表面にバイオフィルムとしてみられる多様な微生物群落であって、宿主および微生物に由来する細胞外高分子マトリックス内に埋め込まれたもの”と定義されている(Marsh, 2004)。歯垢バイオフィルムは歯肉ラインの上および下(それぞれ歯肉縁上および歯肉縁下)に発生する。酸を産生する歯肉縁上の歯垢は齲歯(むし歯)の原因である。歯肉縁下の歯の表面に形成されて歯肉溝の内張り上皮を覆う歯垢は、歯周感染症(すなわち歯肉炎および歯周炎)の発症をもたらす(Rose et al, 2004)。
アクチノマイセス・ビスコーサス ATCC 43146
アクチノマイセス・オドントリチカス ATCC 17929
カンピロバクター・レクタス ATCC 33238
エンテロコッカス・フェカーリス ATCC 10741
フソバクテリウム・ヌクレアタム ATCC 49256
ミクロモナス(ペプトストレプトコッカス)・ミクロス ATCC 33270
ポルフィロモナス・ジンジバリス ATCC 49417
プレボテラ・インターメディア ATCC 25611
ストレプトコッカス・サングイニス ATCC 10556
ストレプトコッカス・オラーリス ATCC 35037
着香剤を含む口内リンス
着香剤を含まない口内リンス
Difco(商標)中和ブロス(約800mL)
強化TSBYE(約400mL)
人工唾液+5%トリプトン+5%酵母エキス(約2,500mL)(AS+T+Y)
0.147g/L 塩化カルシウム(CaCl2)
0.426g/L リン酸ナトリウム(Na2HPO4)
1.68g/L 炭酸水素ナトリウム(NaHCO3)
90〜50mL遠心管
25mL、10mL、5mLおよび0.1mLピペット
ピペットエイドピペッター
9個の無菌エルレンマイヤーフラスコ
無菌試験管
39−各選択寒天、合計312のプレート用(48時間、前還元したもの)
最適増殖培地および選択寒天(培地を24時間、前還元したもの):
CRブロスおよびCR寒天−カンピロバクター・レクタス
BHIBブロスおよびBHIB pH=9.6寒天−エンテロコッカス・フェカーリス
TSBYEインベルターゼ処理ブロスおよびMSss/MSN寒天−ストレプトコッカス・サングイニスおよびストレプトコッカス・オラーリス
シェードラー(Schaedler)ブロスおよびCVE寒天−フソバクテリウム・ヌクレアタム
PmブロスおよびMSCN寒天−ミクロモナス・ミクロス
PgブロスおよびBPB+MUP寒天−ポルフィロモナス・ジンジバリス
BHIBブロスおよびCFAT+MUP寒天−アクチノマイセス・ビスコーサス
ETSBYE−すべての細菌用
血液寒天
安定化した二酸化塩素リンスの殺菌活性の測定を、歯肉炎、歯周の疾患および健康状態に関連する個々の口腔細菌の懸濁液について実施した。下記の細菌を個々にマイクロタイタープレートアッセイシステムによりアッセイした:ポルフィロモナス・ジンジバリス、プレボテラ・インターメディア、フソバクテリウム・ヌクレアタム、ミクロモナス・ミクロス、アクチノマイセス・ビスコーサス、アクチノマイセス・オドントリチカス、ストレプトコッカス・サングイニス、ストレプトコッカス・オラーリス、カンピロバクター・レクタスおよびエンテロコッカス・フェカーリス。
S. oralis ストレプトコッカス・オラーリス
S. sanguinis ストレプトコッカス・サングイニス
A. viscosus アクチノマイセス・ビスコーサス
C. rectus カンピロバクター・レクタス
F. nucleatum フソバクテリウム・ヌクレアタム
M. micros ミクロモナス・ミクロス
P. gingivalis ポルフィロモナス・ジンジバリス
*−−細菌がフラスコの底に付着したのでA660がきわめて低かった。フラスコの底を無菌ループで掻き取ってそれらを懸濁させると、そのアッセイのCFU/mL数は予想どおりになった;
**−−A660による濃度が2倍に見えたが、標準曲線によればわずかな差があり、したがってこの実験は予め計算したとおりに行なわれた。
Claims (21)
- グラム陰性およびグラム陽性歯周細菌が生息する口腔内の微生物環境における細菌を減少および死滅させるための方法であって、約0.5%〜約0.8%(w/v)の範囲の濃度を有する安定化した二酸化塩素の溶液で口腔をすすいで、口腔に存在するグラム陰性およびグラム陽性歯周病原菌の増殖に対する静菌干渉を生じさせる段階を含む、前記方法。
- 歯周疾患に関連する嫌気性細菌および好気性細菌の増殖に対する静菌干渉を生じさせる段階を含む、請求項1に記載の方法。
- タンパク質の産生に干渉してグラム陰性およびグラム陽性歯周病原菌の増殖に負の作用を及ぼす段階を含む、請求項1に記載の方法。
- 少なくとも1種類のDNAおよびRNAの産生に干渉してグラム陰性およびグラム陽性歯周病原菌の増殖に負の作用を及ぼす段階を含む、請求項1に記載の方法。
- 細菌細胞の膜透過性制御を維持する能力に作用を及ぼす段階を含む、請求項1に記載の方法。
- 口腔内のポルフィロモンス・ジンジバリス、プレボテラ・インターメディア、フソブバクテリウム・ヌクレアタム、およびカンピロバクター・レクタスのいずれかを含むグラム陰性歯周病原菌の存在を少なくとも減少させる段階を含む、請求項1に記載の方法。
- アクチノマイセス・オドントリチカス、アクチノマイセス・ビスコス、ストレプトコッカス・サングイニス、ストレプトコッカス・オラーリス、ミクロモナス(ペプトストレプトコッカス)・ミクロス、およびエンテロコッカス・フェカーリスのいずれかを含むグラム陽性歯周細菌の存在を少なくとも減少させる段階を含む、請求項1に記載の方法。
- グラム陰性およびグラム陽性歯周細菌が生息する口腔内の微生物環境における細菌を減少および死滅させるための方法であって、約0.5%〜約0.8%(w/v)の範囲の濃度を有する安定化した二酸化塩素の溶液で口腔をすすぐ段階を含む、前記方法。
- 歯周疾患に関連する嫌気性細菌および嫌気性細菌の増殖に対する静菌干渉を生じさせる段階を含む、請求項8に記載の方法。
- タンパク質の産生に干渉してグラム陰性およびグラム陽性歯周病原菌の増殖に負の作用を及ぼす段階を含む、請求項8に記載の方法。
- 少なくとも1種類のDNAおよびRNAの産生に干渉してグラム陰性およびグラム陽性歯周病原菌の増殖に負の作用を及ぼす段階を含む、請求項8に記載の方法。
- 細菌細胞の膜透過性制御を維持する能力に作用を及ぼす段階を含む、請求項8に記載の方法。
- 口腔内のポルフィロモンス・ジンジバリス、プレボテラ・インターメディア、フソブバクテリウム・ヌクレアタム、およびカンピロバクター・レクタスのいずれかを含むグラム陰性歯周病原菌の存在を少なくとも減少させる段階を含む、請求項8に記載の方法。
- アクチノマイセス・オドントリチカス、アクチノマイセス・ビスコス、ストレプトコッカス・サングイニス、ストレプトコッカス・オラーリス、ミクロモナス(ペプトストレプトコッカス)・ミクロス、およびエンテロコッカス・フェカーリスのいずれかを含むグラム陽性歯周細菌の存在を少なくとも減少させる段階を含む、請求項8に記載の方法。
- カンピロバクター・レクタス、ミクロモナス・ミクロス、ポルフィロモナス・ジンジバリス、フソバクテリウム・ヌクリウタム、ストレプトコッカス・サングイス、エンテロコッカス・フェカーリス、ストレプトコッカス・オラーリス、およびアクチノマイセス・ビスコーサスを含むグラム陰性菌およびグラム陽性菌が生息する口腔内の微生物環境における細菌を減少および死滅させるための方法であって、約0.4%〜約0.8%(w/v)の範囲の濃度を有する安定化した二酸化塩素の溶液で口腔をすすいで、カンピロバクター・レクタス、ミクロモナス・ミクロス、ポルフィロモナス・ジンジバリスおよびフソバクテリウム・ヌクレアタムを最初の1時間以内に死滅させ、ストレプトコッカス・サングイス、エンテロコッカス・フェカーリス、ストレプトコッカス・オブリスおよびアクチノマイセス・ビスコスの存在を最初の1時間以内に減少させ、ストレプトコッカス・サングイス、エンテロコッカス・フェカーリス、ストレプトコッカス・オバリスおよびアクチノマイセス・ビスコスを17時間以内に死滅させる段階を含む、前記方法。
- 安定化した二酸化塩素の溶液が約0.5%〜約0.8%(w/v)の範囲の濃度を有し、ストレプトコッカス・オバリス、およびストレプトコッカス・サングイニス(S. sanguinis)を最初の1時間以内に死滅させる段階を含む、請求項15に記載の方法。
- 安定化した二酸化塩素の溶液が約0.5%〜約0.8%(w/v)の範囲の濃度を有し、安定化した二酸化塩素の溶液に着香剤を添加して、カンピロバクター・レクタス、ポルフィロモナス・ジンジバリス、およびストレプトコッカス・サングイニスを最初の1時間以内に死滅させ、フソバクテリウム・ヌクレアタム、ミクロモナス・ミクロス、エンテロコッカス・フェカーリス、アクチノマイセス・ビスコス、およびストレプトコッカス・オラーリスの存在を最初の1時間以内に減少させ、フソバクテリウム・ヌクレアタム、ミクロモナス・ミクロス、エンテロコッカス・フェカーリス、アクチノマイセス・ビスコーサス、およびストレプトコッカス・オラーリスを17時間以内に死滅させる段階を含む、請求項15に記載の方法。
- 安定化した二酸化塩素の溶液が約0.6%〜約0.8%(w/v)の範囲の濃度を有し、カンピロバクター・レクタス、フソバクテリウム・ヌクレアタム、ポルフィロモナス・ジンジバリス、ミクロモナス・ミクロス、エンテロコッカス・フェカーリス、ストレプトコッカス・オラーリス、およびストレプトコッカス・サングイニスを最初の1時間以内に死滅させ、アクチノマイセス・ビスコーカスの存在を最初の1時間以内に少なくとも減少させ、アクチノマイセス・ビスコーカスを17時間以内に死滅させる段階を含む、請求項15に記載の方法。
- 安定化した二酸化塩素の溶液に着香剤を添加する段階を含む、請求項18に記載の方法。
- 安定化した二酸化塩素の溶液が少なくとも約0.8%(w/v)の濃度を有し、カンピロバクター・レクタス、フソバクテリウム・ヌクレアタム、ポルフィロモナス・ジンジバリス、ミクロモナス・ミクロス、エンテロコッカス・フェカーリス、アクチノマイセス・ビスコーサス、ストレプトコッカス・オラーリス、およびストレプトコッカス・サングイニスを最初の1分以内に死滅させる段階を含む、請求項15に記載の方法。
- 安定化した二酸化塩素の溶液に着香剤を添加する段階を含む、請求項20に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/774,730 US20090016973A1 (en) | 2007-07-09 | 2007-07-09 | Composition and Method for the Prevention of Oral Disease |
US11/774,730 | 2007-07-09 | ||
PCT/US2008/055154 WO2009009163A1 (en) | 2007-07-09 | 2008-02-27 | Composition and method for the prevention of oral disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013217385A Division JP6087781B2 (ja) | 2007-07-09 | 2013-10-18 | 口腔疾患を予防するための組成物および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010533189A true JP2010533189A (ja) | 2010-10-21 |
JP5714900B2 JP5714900B2 (ja) | 2015-05-07 |
Family
ID=40224433
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010516078A Expired - Fee Related JP5714900B2 (ja) | 2007-07-09 | 2008-02-27 | 口腔疾患を予防するための組成物および方法 |
JP2013217385A Expired - Fee Related JP6087781B2 (ja) | 2007-07-09 | 2013-10-18 | 口腔疾患を予防するための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013217385A Expired - Fee Related JP6087781B2 (ja) | 2007-07-09 | 2013-10-18 | 口腔疾患を予防するための組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090016973A1 (ja) |
EP (2) | EP2200441B1 (ja) |
JP (2) | JP5714900B2 (ja) |
CA (1) | CA2623769C (ja) |
ES (2) | ES2543132T3 (ja) |
HK (2) | HK1143929A1 (ja) |
WO (1) | WO2009009163A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015526503A (ja) * | 2012-08-27 | 2015-09-10 | ユニバーシティ オブ プレトリア | 口腔ケア |
JP2019004888A (ja) * | 2016-07-11 | 2019-01-17 | 三菱ケミカル株式会社 | 口腔内検査方法 |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7383423B1 (en) * | 2004-10-01 | 2008-06-03 | Advanced Micro Devices, Inc. | Shared resources in a chip multiprocessor |
US8926951B2 (en) * | 2007-07-09 | 2015-01-06 | Micropure, Inc. | Composition for preventing oral disease by penetrating polymicrobial oral biofilms and killing oral pathogens |
WO2010036427A1 (en) | 2008-06-17 | 2010-04-01 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
US20100009009A1 (en) | 2008-07-10 | 2010-01-14 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
WO2010009063A2 (en) | 2008-07-15 | 2010-01-21 | Basf Corporation | Non-cytotoxic chlorine dioxide fluids |
CL2009001581A1 (es) * | 2008-07-15 | 2010-09-10 | Basf Corp | Metodo para pulir una superficie dental, donde se pone en contacto dicha superficie con una composicion de pulido sustancialmente no irritante y comprende dioxido de cloro; |
US20100062042A1 (en) * | 2008-07-15 | 2010-03-11 | Basf Catalysts Llc | Methods, Systems and Devices for Administration of Chlorine Dioxide |
US8311625B2 (en) | 2009-02-04 | 2012-11-13 | Basf Corporation | Chlorine dioxide treatment for biological tissue |
US20100233101A1 (en) * | 2009-02-13 | 2010-09-16 | Micropure, Inc. | Composition and method for the oxidative consumption of salivary biomolecules |
EP2429308A4 (en) * | 2009-05-01 | 2012-11-14 | Basf Corp | GUM AND SUGAR BASED ON CHLORINE DIOXIDE |
US8992831B2 (en) | 2009-09-25 | 2015-03-31 | E. I. Du Pont De Nemours And Company | Stabilized chlorine dioxide to preserve carbohydrate feedstocks |
WO2011094657A2 (en) | 2010-01-31 | 2011-08-04 | Basf Corporation | Additives for chlorine dioxide-containing compositions |
ES2725784T3 (es) | 2011-07-20 | 2019-09-27 | Univ Brigham Young | Compuestos de ceragenina hidrófobos y dispositivos que incorporan al mismo |
US9694019B2 (en) | 2011-09-13 | 2017-07-04 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
JP6038154B2 (ja) | 2011-09-13 | 2016-12-07 | ブリガム・ヤング・ユニバーシティBrigham Young University | 骨疾患および破断骨治療のための組成物 |
US9603859B2 (en) | 2011-09-13 | 2017-03-28 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
WO2013040269A1 (en) | 2011-09-13 | 2013-03-21 | Brigham Young University | Products for healing of tissue wounds |
AU2011385377B2 (en) | 2011-12-21 | 2017-06-01 | Brigham Young University | Oral care compositions |
US20140363780A1 (en) * | 2011-12-21 | 2014-12-11 | Brigham Young University | Oral care compositions |
GB201202341D0 (en) | 2012-02-10 | 2012-03-28 | Periproducts Ltd | Multicomponent oral care compostion |
US9533063B1 (en) | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
EP3225113B1 (en) | 2012-05-02 | 2020-09-02 | Brigham Young University | Methods for making ceragenin particulate materials |
EP2908826A1 (en) | 2012-10-17 | 2015-08-26 | Brigham Young University | Treatment and prevention of mastitis |
KR102203375B1 (ko) | 2013-01-07 | 2021-01-15 | 브라이엄 영 유니버시티 | 세포 증식을 감소시키는 방법 및 소정의 질환을 치료하는 방법 |
CN110420211A (zh) | 2013-03-15 | 2019-11-08 | 布莱阿姆青年大学 | 治疗炎症、自身免疫性疾病和疼痛的方法 |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
US10568893B2 (en) | 2013-03-15 | 2020-02-25 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
US10471109B2 (en) | 2013-05-04 | 2019-11-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for promoting nitric oxide production through an oral delivery system |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
CA2844321C (en) | 2014-02-27 | 2021-03-16 | Brigham Young University | Cationic steroidal antimicrobial compounds |
US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
US9686966B2 (en) | 2014-04-30 | 2017-06-27 | Brigham Young University | Methods and apparatus for cleaning or disinfecting a water delivery system |
US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
US10227376B2 (en) | 2014-08-22 | 2019-03-12 | Brigham Young University | Radiolabeled cationic steroid antimicrobials and diagnostic methods |
US10155788B2 (en) | 2014-10-07 | 2018-12-18 | Brigham Young University | Cationic steroidal antimicrobial prodrug compositions and uses thereof |
WO2016172553A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
WO2016172543A1 (en) | 2015-04-22 | 2016-10-27 | Savage Paul B | Methods for the synthesis of ceragenins |
US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
US20170157013A1 (en) * | 2015-12-07 | 2017-06-08 | Colgate-Palmolive Company | Metal Amino Acid Complexes for Bacterial Aggregation |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
CA3020197C (en) | 2017-09-01 | 2024-06-04 | Micropure, Inc. | Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200171A (en) * | 1990-11-20 | 1993-04-06 | Micropure, Inc. | Oral health preparation and method |
EP0613678A1 (en) * | 1986-12-29 | 1994-09-07 | Micropure, Inc. | Oral care composition |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3271242A (en) * | 1963-03-29 | 1966-09-06 | Alexander R Reed Iii | Stable chlorine dioxide composition and method of making same |
JPS6054311A (ja) * | 1983-09-04 | 1985-03-28 | Mitsuru Tsuchikura | 口臭に係る消臭殺菌溶液。 |
US4855135A (en) * | 1984-07-30 | 1989-08-08 | Ratcliff Perry A | Method for debriding |
US4818519A (en) * | 1986-12-29 | 1989-04-04 | Ratcliff Perry A | Method and composition for prevention of plaque formation and plaque dependent diseases |
US4975285A (en) * | 1984-07-30 | 1990-12-04 | Ratcliff Perry A | Method for cleaning dental prosthetic devices |
US4793989A (en) * | 1984-07-30 | 1988-12-27 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4689215A (en) * | 1984-07-30 | 1987-08-25 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4889714A (en) * | 1984-07-30 | 1989-12-26 | Ratcliff Perry A | Method for retarding dental plaque by killing streptococcus sanguis |
US4696811A (en) * | 1984-07-30 | 1987-09-29 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4886657A (en) * | 1984-07-30 | 1989-12-12 | Ratcliff Perry A | Method for preventing periodontitis |
US4788053A (en) * | 1984-07-30 | 1988-11-29 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4837009A (en) * | 1986-03-31 | 1989-06-06 | Ratcliff Perry A | Method and composition for prevention of plaque formation and plaque dependent diseases |
US4792442A (en) * | 1986-03-31 | 1988-12-20 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4925656A (en) * | 1986-03-31 | 1990-05-15 | Ratcliff Perry A | Method for retarding formation of dental plaque |
US4786492A (en) * | 1986-03-31 | 1988-11-22 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4851213A (en) * | 1986-03-31 | 1989-07-25 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease due to S. Sanguis |
US4808389A (en) * | 1986-12-29 | 1989-02-28 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US5348734A (en) * | 1990-11-20 | 1994-09-20 | Micropure Inc. | Oral health preparation and method |
US5284648A (en) * | 1989-03-17 | 1994-02-08 | White Robert D | Alcohol-free, oral rinse and pre-rinse emulsions method of prepration and method of use |
US5281412A (en) * | 1991-12-30 | 1994-01-25 | The Procter & Gamble Company | Oral compositions |
US6200557B1 (en) * | 1993-07-06 | 2001-03-13 | Perry A. Ratcliff | Method of treating HIV by a topical composition |
US5489435A (en) * | 1993-07-06 | 1996-02-06 | Ratcliff; Perry A. | Composition for treatment of abnormal conditions of the epithelium of bodily orifices |
AU2204995A (en) * | 1994-04-07 | 1995-10-30 | Jon L. Richter | Oral rinse and method of treating halitosis |
US6350438B1 (en) * | 1998-02-27 | 2002-02-26 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
US6132702A (en) * | 1998-02-27 | 2000-10-17 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
US6846478B1 (en) * | 1998-02-27 | 2005-01-25 | The Procter & Gamble Company | Promoting whole body health |
US6391577B1 (en) * | 1999-03-03 | 2002-05-21 | Susan R. Mikkelsen | Rapid electrochemical assay for antibiotic and cytotoxic drug susceptibility in microorganisms |
US6231830B1 (en) * | 1999-03-04 | 2001-05-15 | George Madray | Method of making molecular chlorine dioxide |
US7087228B2 (en) * | 2002-07-03 | 2006-08-08 | University Of Southern California | Preventing tooth decay and infective endocarditis using natural oligopeptides |
-
2007
- 2007-07-09 US US11/774,730 patent/US20090016973A1/en not_active Abandoned
-
2008
- 2008-02-27 JP JP2010516078A patent/JP5714900B2/ja not_active Expired - Fee Related
- 2008-02-27 EP EP08743577.2A patent/EP2200441B1/en active Active
- 2008-02-27 ES ES08743577.2T patent/ES2543132T3/es active Active
- 2008-02-27 WO PCT/US2008/055154 patent/WO2009009163A1/en active Search and Examination
- 2008-02-27 ES ES14193943.9T patent/ES2682457T3/es active Active
- 2008-02-27 EP EP14193943.9A patent/EP2921174B1/en active Active
- 2008-02-29 CA CA2623769A patent/CA2623769C/en active Active
-
2010
- 2010-11-11 HK HK10110512.6A patent/HK1143929A1/xx not_active IP Right Cessation
-
2013
- 2013-10-18 JP JP2013217385A patent/JP6087781B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-18 HK HK16100497.0A patent/HK1212598A1/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0613678A1 (en) * | 1986-12-29 | 1994-09-07 | Micropure, Inc. | Oral care composition |
US5200171A (en) * | 1990-11-20 | 1993-04-06 | Micropure, Inc. | Oral health preparation and method |
Non-Patent Citations (2)
Title |
---|
JPN6012068101; 口腔衛生学会雑誌 Vol.56 No.4, 2006, p.565 * |
JPN6012068103; 日本口腔インプラント学会誌 Vol.18 No.2, 2005, pp.222-228 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015526503A (ja) * | 2012-08-27 | 2015-09-10 | ユニバーシティ オブ プレトリア | 口腔ケア |
JP2019004888A (ja) * | 2016-07-11 | 2019-01-17 | 三菱ケミカル株式会社 | 口腔内検査方法 |
JP2020141686A (ja) * | 2016-07-11 | 2020-09-10 | 三菱ケミカル株式会社 | 口腔内検査方法 |
JP7122337B2 (ja) | 2016-07-11 | 2022-08-19 | 株式会社ジーシー | 口腔内検査方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2200441A4 (en) | 2011-01-05 |
HK1212598A1 (zh) | 2016-06-17 |
JP2014040470A (ja) | 2014-03-06 |
EP2921174B1 (en) | 2018-05-16 |
JP6087781B2 (ja) | 2017-03-01 |
JP5714900B2 (ja) | 2015-05-07 |
EP2200441A1 (en) | 2010-06-30 |
ES2543132T3 (es) | 2015-08-14 |
WO2009009163A1 (en) | 2009-01-15 |
EP2921174A1 (en) | 2015-09-23 |
ES2682457T3 (es) | 2018-09-20 |
CA2623769C (en) | 2019-02-12 |
EP2200441B1 (en) | 2014-12-10 |
HK1143929A1 (en) | 2011-01-21 |
US20090016973A1 (en) | 2009-01-15 |
CA2623769A1 (en) | 2009-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5714900B2 (ja) | 口腔疾患を予防するための組成物および方法 | |
EP0923939B1 (en) | Haloperoxidase for the treatment of infection and control of flora | |
Ekmekcioglu et al. | Effect of sulfur baths on antioxidative defense systems, peroxide concentrations and lipid levels in patients with degenerative osteoarthritis | |
EP2549877B1 (en) | Composition for preventing oral disease | |
Siqueira Jr et al. | Stimulated whole saliva components in children with Down syndrome | |
Shimada et al. | A comparison of the bactericidal effects and cytotoxic activity of three types of oxidizing water, prepared by electrolysis, as chemical dental plaque control agents | |
Buzia¹ et al. | Antibacterial action of certain tretinoin and benzoyl peroxide liposomes. Case study | |
Kim et al. | The effects of xylitol and sorbitol on lysozyme-and peroxidase-related enzymatic and candidacidal activities | |
Cho et al. | Interactions between hyaluronic acid, lysozyme, and the glucose oxidase-mediated lactoperoxidase system in enzymatic and candidacidal activities | |
JP6667501B2 (ja) | 生存菌類寄生微生物ピシウム・オリガンドラムを含む、皮膚および粘膜の皮膚糸状菌症および酵母感染症の処置用製剤、微生物ピシウム・オリガンドラムの細胞生存率を決定する方法ならびに該製剤の適用方法 | |
Wagenknecht et al. | Analyses of the effects of arginine, nicotine, serotype and collagen-binding proteins on biofilm development by 33 strains of Streptococcus mutans | |
RU2264220C2 (ru) | Медно-серебряный ионатор и лечебное средство с антимикробным действием | |
Berger et al. | Cyclical abnormalities in the bactericidal function, superoxide production, and lysozyme activity of neutrophils obtained from a healthy woman during menstruation: reversal by pretreatment with aspirin | |
CN114681350B (zh) | 一种含溶菌酶的清洁剂组合物 | |
Šadzevičienė et al. | Oxidative function of neutrophils in periodontitis patients with type 1 diabetes mellitus | |
Камилов et al. | ETIOPATHOGENETIC CHARACTERISTICS OF CHRONIC CATARRHAL GINGIVITIS | |
Klitynska et al. | Peculiarities of free radical oxidation and antioxidant protection parameters of the oral fluid in children with chronic catarrhal gingivitis with underlying diabetes mellitus | |
Amtha et al. | A Comparison of Commercial Mouthwashes Towards Oral Pathogens Biofilms in vitro | |
Sangha | Proanthocyanidin-rich cranberry-fraction-induced alteration of periodontal pathogen lipopolysaccharide functions | |
JPH0124136B2 (ja) | ||
Price | Fluoride Effects on the Growth of Oral Bacteria Streptococcus mutans, Streptococcus mitis, and Lactobacillius acidophilus and Their Protein Expressions | |
Al–Azzawi et al. | A histochemical study of the peroxidase enzyme activity associated with paradontal abscess | |
Bahng | Antioxidants as Risk Factors for Gingival Bleeding | |
Krishan et al. | Antioxidant Enzymes as Markers of Human Periapical Lesions: Are Lipid Peroxides Responsible? | |
Machida et al. | Anti-aging Effects of Co-enzyme Q10 on Periodontal Tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130502 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131018 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131105 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20131206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150312 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5714900 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |